Company intelligence / Profile preview

Ascend Biopharmaceuticals Ltd.

South Melbourne, Victoria, Australiaprnewswire.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

Positive results from Phase 2 study of SP-002 (formerly ASN-002) in combination with vismodegib in multi-lesional Basal Cell Carcinoma patients announced in January 2025. The study demonstrated safety and efficacy of their gene therapy for patients with multiple nodular and superficial BCCs, with identification of histopathologic criteria for patient selection.

Therapeutic areas: OncologyDermatology
Modalities: Cancer immunotherapyGene therapyAdenovirus vector (Ad-IFNγ)
Industry: Biotech

Drug pipeline

4 assets

AFM13

Phase 2

Indications: Hodgkin Lymphoma, CD30-positive lymphoma

3 more assets in the full pipeline.

Request access →

Partnerships

Stamford Pharmaceuticals (appears to be developing SP-002, formerly ASN-002)

Beyond the preview

Go deeper on Ascend Biopharmaceuticals Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascend Biopharmaceuticals Ltd..

Explore the full profile